Janssen Pharmaceutica Nv

Orapharma, Inc.

Bharat Lagu

Michael P Wachter

Barbara A Pio

Rimma Lebedev

Peter J Connolly

Stuart Emanuel

Steven A Middleton

Mingde Xia

Sigmond G Johnson

Niranjan B Pandey

Kenneth C Rupert

Fina Liotta

Meng Pan

Mark Powell

Stuart Hayden

The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating RXR mediated disorders. More particularly, the compounds of the present invention are RXR agonists useful for treating RXR mediated disorders.

Dihydro-[1H]-quinolin-2-one derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes

Quaternary salt compounds of Formula (I) or pharmaceutically acceptable forms thereof, which are CCR2 antagonists and are useful in preventing, treating or ameliorating CCR2 mediated inflammatory syndromes, disorders or diseases in a subject in need thereof.

Quaternary salt CCR2 antagonists

Heterocyclic amide derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes

Dihydro-1[1H]-quinolin-2-one derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes

This invention is directed to a tetrahydro-indazole cannabinoid modulator compound of formula I: and a method for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.

Tetrahydro-indazole cannabinoid modulators

The present invention is directed to substituted thiatriazaacenaphthylene-6-carbonitrile compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.

Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors

This invention is directed to heterocyclyl-substituted anilino phospholipase C inhibitor compounds useful in treating or ameliorating an inflammatory disorders and/or restenosis of the general formula (I): and enantiomers, diastereomers and pharmaceutically acceptable salts thereof. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions affected by phospholipase modulation.

Phospholipase C inhibitors for use in treating inflammatory disorders

Growing community of inventors

Hillsborough, NJ, United States of America

Bharat Lagu